Nektar Therapeutics NKTR Cash Flow Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| —— | -$44.9M-24.5% | -$36.08M-1.6% | -$35.52M+14.6% | -$41.59M+18.3% | ||
| —— | $151K-20.5% | $190K-3.1% | $196K-8.4% | $214K-49.8% | ||
| —— | $3.36M+53.0% | $2.19M-28.6% | $3.07M-11.9% | $3.49M-10.6% | ||
| —— | -$934K+80.5% | -$4.79M-474% | $1.28M+136% | -$3.52M-155% | ||
| —— | $2.33M+185% | -$2.72M+61.1% | -$7M-357% | $2.73M+124% | ||
| —— | -$949K-110% | $9.86M+1,495% | $618K— | $0-100% | ||
| —— | -$1.75M-30.0% | -$1.35M-152% | -$534K+77.6% | -$2.39M+46.5% | ||
| —— | -$1.66M+11.9% | -$1.89M-31.8% | -$1.43M-64.9% | -$869K+34.4% | ||
| —— | -$44.3M+31.8% | -$64.96M-33.2% | -$48.76M-6.6% | -$45.74M+6.8% | ||
| —— | $18K0.0% | $18K-84.2% | $114K+208% | $37K+1,750% | ||
| —— | $452.25M+394% | $91.6M-38.8% | $149.56M+690% | $18.92M-24.1% | ||
| —— | $101.48M+10.3% | $91.99M+67.9% | $54.8M-20.1% | $68.57M-1.1% | ||
| —— | -$350.79M— | —— | -$94.87M-291% | $49.62M+13.6% | ||
| $1.07B— | —— | $410K+72.3% | $238K+12.8% | $211K+2,914% | ||
| —— | $529.55M+1,269% | $38.67M-72.7% | $141.68M+67,045% | $211K+2,914% | ||
| —— | $0— | $0-100% | $1K-83.3% | $6K+700% | ||
| —— | $134.46M+619% | -$25.92M-1,225% | -$1.96M— | —— | ||
| —— | $3.36M+53.0% | $2.19M-28.6% | $3.07M-11.9% | $3.49M-10.6% | ||
| —— | -$1.66M+11.9% | -$1.89M-31.8% | -$1.43M-64.9% | -$869K+34.4% | ||
| —— | —— | $0— | $0— | $0— | ||
| —— | -$1.75M-30.0% | -$1.35M-152% | -$534K+77.6% | -$2.39M+46.5% | ||
| —— | $2.41M-58.1% | $5.75M+50.2% | $3.83M+1.6% | $3.77M+108% | ||
| —— | $2.33M+185% | -$2.72M+61.1% | -$7M-357% | $2.73M+124% | ||
| —— | -$949K-110% | $9.86M+1,495% | $618K— | $0-100% | ||
| —— | $7.94M-18.7% | $9.77M+61.6% | $6.05M+12.1% | $5.39M+8.4% | ||
| —— | $10.86M-50.2% | $21.81M+89.8% | $11.49M+2.8% | $11.18M+6.8% | ||
| —— | $0— | —— | —— | —— | ||
| —— | $101.48M+10.3% | $91.99M+67.9% | $54.8M-20.1% | $68.57M-1.1% | ||
| —— | —— | -$174.25K0.0% | -$174.25K0.0% | -$174.25K0.0% | ||
| —— | $25K— | —— | —— | —— | ||
| —— | $4.06M+889% | $410K+72.3% | $238K+12.8% | $211K+2,914% | ||
| —— | —— | $0— | $0— | $0— | ||
| —— | —— | $0— | $0— | $0— | ||
| —— | -$44.32M+31.8% | -$64.98M-32.9% | -$48.88M-6.8% | -$45.78M+6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Nektar Therapeutics's cash flow data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.